

Juan A Pineda

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4191807/juan-a-pineda-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296 papers	6,452 citations	42 h-index	63 g-index
321 ext. papers	7,563 ext. citations	5.8 avg, IF	5.01 L-index

#	Paper	IF	Citations
296	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
295	Incidence of recently acquired hepatitis C virus infection among HIV-infected patients in southern Spain. <i>HIV Medicine</i> , 2021 , 22, 379-386	2.7	3
294	Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. <i>Clinical Infectious Diseases</i> , 2021 , 73, e2109-e2116	11.6	5
293	Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 878-886	3.4	
292	Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. <i>PLoS ONE</i> , 2021 , 16, e0249036	3.7	1
291	Liver stiffness change with HCV cure in HIV-infected patients on non-nucleoside analogues. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2375-2379	5.1	0
290	Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response. <i>Aids</i> , 2021 , 35, 2119-2127	3.5	0
289	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
288	Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response. <i>Clinical Infectious Diseases</i> , 2021 , 72, e96-e102	11.6	2
287	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study.. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
286	Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. <i>Scientific Reports</i> , 2020 , 10, 6736	4.9	2
285	Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. <i>Current HIV/AIDS Reports</i> , 2020 , 17, 6-17	5.9	6
284	How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. <i>HIV Medicine</i> , 2020 , 21, 128-134	2.7	
283	Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2810-2817	11.6	7
282	Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. <i>Aids</i> , 2020 , 34, 1497-1507	3.5	3
281	Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2354-2362	11.6	17
280	Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 , 38, 28-32	0.9	9

279	Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 , 38, 127-131	0.9	4
278	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1333-1347	1.2	45
277	Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. <i>PLoS ONE</i> , 2019 , 14, e0221231	3.7	9
276	Evaluation of hepatitis C viral RNA persistence in HIV-infected patients with long-term sustained virological response by droplet digital PCR. <i>Scientific Reports</i> , 2019 , 9, 12507	4.9	7
275	A genome-wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). <i>Liver International</i> , 2019 , 39, 1918-1926	7.9	1
274	Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection. <i>Scientific Reports</i> , 2019 , 9, 9054	4.9	1
273	Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks. <i>Journal of Infection</i> , 2019 , 79, 30-35	18.9	4
272	Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability. <i>Infection, Genetics and Evolution</i> , 2019 , 73, 276-286	4.5	1
271	Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. <i>Journal of Hepatology</i> , 2019 , 71, 45-51	13.4	30
270	Hepatitis C virus infection in Spain: Challenges in the track to elimination. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019 , 37, 219-221	0.1	
269	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 296-304	2.2	26
268	Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 16-24	3.4	11
267	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV. <i>Journal of Hepatology</i> , 2019 , 71, 876-888	10.8	19
266	High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world. <i>Journal of Hepatology</i> , 2019 , 71, 876-888	13.4	8
265	Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. <i>Journal of Hepatology</i> , 2019 , 71, 1270-1272	13.4	6
264	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019 , 42, 579-592	0.1	2
263	Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain. <i>Eurosurveillance</i> , 2019 , 24,	19.8	13
262	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Revista Espanola De Enfermedades Digestivas</i> , 2019 , 111, 862-873	0.9	4

261	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEHH). <i>Gastroenterología Y Hepatología</i> , 2019 , 42, 579-592	0.9	13
260	HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. <i>Aids</i> , 2019 , 33, 1167-1174	3.5	12
259	Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2019 , 33, 269-278	3.5	7
258	Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 48-54	3.4	3
257	Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice. <i>HIV Clinical Trials</i> , 2018 , 19, 23-30		3
256	Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 699-706	3.4	12
255	Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2018 , 32, 1423-1430	3.5	17
254	Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 268-276	0.9	5
253	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , 2018 , 5, e23-e34	7.8	64
252	Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unravelling by phylogenetic analysis. <i>PLoS ONE</i> , 2018 , 13, e0201268	3.7	11
251	Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2435-2443	5.1	12
250	Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. <i>Antiviral Research</i> , 2018 , 150, 9-14	10.8	14
249	Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 180-186	3.4	4
248	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEHH). <i>Gastroenterología Y Hepatología</i> , 2018 , 41, 597-608	0.9	10
247	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEHH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018 , 41, 597-608	0.1	
246	Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. <i>Scientific Reports</i> , 2018 , 8, 14905	4.9	4
245	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018 , 155, 1120-1127.e4	13.3	47
244	HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. <i>Pharmacogenomics Journal</i> , 2017 , 17, 551-555	3.5	5

243	KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy. <i>Pharmacogenomics Journal</i> , 2017 , 17, 360-365	3.5	5
242	Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 409.e5-409.e8	9.5	8
241	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017 , 18, 546-554	2.7	4
240	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017 , 11, 188-198	8.8	2
239	Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals. <i>Journal of Infection</i> , 2017 , 74, 514-517	18.9	1
238	Rural habitat as risk factor for hepatitis E virus seroconversion in HIV-infected patients: A prospective longitudinal study. <i>Zoonoses and Public Health</i> , 2017 , 64, e60-e64	2.9	10
237	Liver stiffness predicts variceal bleeding in HIV/HCV-coinfecting patients with compensated cirrhosis. <i>Aids</i> , 2017 , 31, 493-500	3.5	20
236	HIV-coinfecting patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfecting individuals: a prospective cohort study. <i>HIV Clinical Trials</i> , 2017 , 18, 126-134		29
235	Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 853-861	5.3	4
234	Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. <i>Aids</i> , 2017 , 31, 89-95	3.5	13
233	HLA-B18 as risk factor of liver fibrosis progression in HIV/HCV treatment-experienced patients. <i>Pharmacogenomics Journal</i> , 2017 , 17, 479-480	3.5	2
232	Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2017 , 35, 88-99	0.9	6
231	High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfecting patients in clinical practice. <i>HIV Medicine</i> , 2017 , 18, 445-451	2.7	8
230	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1012-1019	11.6	23
229	Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial. <i>Antiviral Therapy</i> , 2017 , 22, 263-269	1.6	6
228	Non-Alcoholic Fatty Liver Disease in HIV Infection. <i>AIDS Reviews</i> , 2017 , 19, 35-46	1.5	10
227	Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users. <i>Infection, Genetics and Evolution</i> , 2016 , 45, 20-25	4.5	5
226	HCV epidemiology in high-risk groups and the risk of reinfection. <i>Journal of Hepatology</i> , 2016 , 65, S33-S45	3.4	111

225	No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: a multicentric retrospective study from 2000-2014. <i>BMC Infectious Diseases</i> , 2016 , 16, 489	4	5
224	Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. <i>International Journal of Infectious Diseases</i> , 2016 , 53, 46-51	10.5	2
223	Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2016 , 28, 1253-7	2.2	1
222	MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. <i>PLoS ONE</i> , 2016 , 11, e0155245	3.7	16
221	Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPatic Study. <i>PLoS ONE</i> , 2016 , 11, e0155842	3.7	3
220	Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. <i>PLoS ONE</i> , 2016 , 11, e0148104	3.7	5
219	The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. <i>PLoS ONE</i> , 2016 , 11, e0168265	3.7	10
218	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016 , 17, 766-773	2.7	17
217	Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes. <i>Antiviral Research</i> , 2015 , 120, 79-84	10.8	13
216	Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1929-36	5.3	6
215	Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1879-84	5.3	2
214	Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 2171-5	5.3	1
213	Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. <i>Journal of Infection</i> , 2015 , 71, 571-7	18.9	39
212	Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). <i>Clinical Microbiology and Infection</i> , 2015 , 21, 105.e1-5	9.5	8
211	Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 104.e1-5	9.5	6
210	High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients. <i>Journal of Infection</i> , 2015 , 70, 624-30	18.9	23
209	Impact of IL28B genotype on first-week response to telaprevir-based therapy in HIV-HCV coinfection. <i>Antiviral Therapy</i> , 2015 , 20, 407-13	1.6	
208	Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. <i>BMC Infectious Diseases</i> , 2015 , 15, 557	4	8

207	Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. <i>Aids</i> , 2015 , 29, 1927-35	3.5	16
206	IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015 , 29, 1895-7	3.5	17
205	Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. <i>PLoS ONE</i> , 2015 , 10, e0125080	3.7	10
204	Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. <i>PLoS ONE</i> , 2015 , 10, e0143492	3.7	
203	Absence of occult Hepatitis E virus infection among HIV immunosuppressed patients. <i>Journal of Infection</i> , 2015 , 70, 680-3	18.9	8
202	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> , 2015 , 16, 72-80		7
201	Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term. <i>Hepatology</i> , 2015 , 61, 1503-11	11.2	10
200	Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 496-503	3.4	15
199	High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015 , 33, 532-5	0.9	7
198	Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection. <i>Genes and Immunity</i> , 2015 , 16, 134-41	4.4	6
197	Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1837-48	4	6
196	Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2014 , 32, 447-58	0.9	10
195	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014 , 68, 372-7	18.9	3
194	HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. <i>Aids</i> , 2014 , 28, 41-7	3.5	27
193	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians. <i>PLoS ONE</i> , 2014 , 9, e95515	3.7	20
192	HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients. <i>PLoS ONE</i> , 2014 , 9, e99468	3.7	2
191	Incidence of hepatitis C virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: increasing rates of HCV diagnosis but not of HCV seroconversions. <i>PLoS ONE</i> , 2014 , 9, e116226	3.7	19
190	Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. <i>Archives of Virology</i> , 2014 , 159, 3345-51	2.6	3

189	A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate. <i>Clinical Infectious Diseases</i> , 2014 , 58, 130-3	11.6	3
188	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014 , 18, 700-8	2.1	9
187	Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting. <i>HIV Medicine</i> , 2014 , 15, 417-24	2.7	16
186	A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers. <i>Liver International</i> , 2014 , 34, 558-66	7.9	7
185	Association of low-density lipoprotein receptor genotypes with hepatitis C viral load. <i>Genes and Immunity</i> , 2014 , 15, 16-24	4.4	15
184	Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients. <i>Aids</i> , 2014 , 28, 1931-7	3.5	40
183	Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. <i>Aids</i> , 2014 , 28, 1279-87	3.5	46
182	Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection. <i>Molecular Biology and Evolution</i> , 2014 , 31, 2402-14	8.3	18
181	Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 4027-9	9.7	22
180	Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV. <i>Lancet Infectious Diseases</i> , 2014 , 14, 13-14	25.5	2
179	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , 2014 , 19, 407-14	1.6	5
178	Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. <i>Infection</i> , 2013 , 41, 21-6	5.8	6
177	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013 , 85, 1734-40	19.7	8
176	Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013 , 32, 1427-35	5.3	9
175	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013 , 67, 59-64	18.9	9
174	Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2013 , 31, 424-9	0.9	7
173	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013 , 27, 81-5	3.5	48
172	Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1646-53	11.6	69

171	Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. <i>Clinical Infectious Diseases</i> , 2013 , 56, 143-50	11.6	56
170	Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection. <i>Aids</i> , 2013 , 27, 1697-706	3.5	18
169	Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. <i>Clinical Infectious Diseases</i> , 2013 , 57, 1401-8	11.6	20
168	Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection. <i>Journal of Infectious Diseases</i> , 2013 , 207, 411-9	7	21
167	Chronic hepatitis E in HIV patients: rapid progression to cirrhosis and response to oral ribavirin. <i>Clinical Infectious Diseases</i> , 2013 , 57, 465-8	11.6	76
166	Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2013 , 29, 223-5	1.6	0
165	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 915-21	5.1	3
164	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013 , 27, 2707-14	3.5	12
163	Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 905-11	2.2	29
162	Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2013 , 27, 2541-9	3.5	26
161	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013 , 27, 2715-24	3.5	7
160	Natural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patients. <i>PLoS ONE</i> , 2013 , 8, e61992	3.7	25
159	Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. <i>PLoS ONE</i> , 2013 , 8, e68953	3.7	27
158	Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. <i>Journal of Infection</i> , 2012 , 64, 204-11	18.9	8
157	A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. <i>Journal of Immunology</i> , 2012 , 188, 818-23	5.3	87
156	Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 2083-8	5.3	13
155	Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. <i>Liver International</i> , 2012 , 32, 1031-2	7.9	9
154	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012 , 56, 788-94	13.4	33

153	Low prevalence of occult HBV infection among HIV-infected patients in Southern Spain. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012 , 30, 312-4	0.9	7
152	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2012 , 56, 1261-70	11.2	30
151	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012 , 9, 68	3.6	7
150	HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. <i>Antiviral Research</i> , 2012 , 95, 212-5	10.8	6
149	Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN- α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. <i>PLoS ONE</i> , 2012 , 7, e28115	3.7	6
148	Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients. <i>PLoS ONE</i> , 2012 , 7, e48959	3.7	2
147	Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012 , 31, 1225-32	5.3	6
146	Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. <i>Hepatology</i> , 2012 , 56, 228-38	11.2	65
145	No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. <i>Antiviral Research</i> , 2012 , 95, 67-71	10.8	2
144	Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. <i>Clinical Infectious Diseases</i> , 2012 , 55, 1719-26	11.6	16
143	Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 407-13	9.7	34
142	Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 202-5	5.1	16
141	Genetic variability at the TREG1 locus is not associated with natural resistance to HIV-1 infection. <i>Aids</i> , 2012 , 26, 1443-5	3.5	5
140	Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. <i>Aids</i> , 2012 , 26, 1721-4	3.5	13
139	Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon- α 2a for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. <i>Journal of Infectious Diseases</i> , 2012 , 206, 961-8	7	18
138	Differences in virological response to peginterferon- α 2a plus ribavirin in HIV-positive patients coinfecting with HCV subtypes 1a or 1b. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, 117-23	3.1	12
137	Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. <i>HIV Clinical Trials</i> , 2012 , 13, 61-9		16
136	LDLR genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. <i>Aids</i> , 2012 , 26, 1009-15	3.5	10

135	HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. <i>Antiviral Therapy</i> , 2011 , 16, 585-9	1.6	14
134	Host genetics. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 491-500	4.2	4
133	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfected patients with prior nonresponse or relapse. <i>Aids</i> , 2011 , 25, 1131-3	3.5	20
132	Influence of the combination of low-density lipoprotein receptor and interleukin 28B genotypes on lipid plasma levels in HIV/hepatitis C-coinfected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 58, e115-7	3.1	
131	Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. <i>HIV Medicine</i> , 2011 , 12, 14-21	2.7	15
130	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. <i>HIV Medicine</i> , 2011 , 12, 487-93	2.7	15
129	Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. <i>AIDS Patient Care and STDs</i> , 2011 , 25, 395-402	5.8	6
128	Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1346-50	5.1	16
127	Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2605-14	5.1	18
126	Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2011 , 203, 1629-36	7	55
125	Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 2838-42	5.1	18
124	Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C. <i>Clinical Infectious Diseases</i> , 2011 , 53, 1291-5	11.6	13
123	Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1351-3	5.1	8
122	Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. <i>Aids</i> , 2011 , 25, 1415-20	3.5	36
121	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011 , 25, 761-6	3.5	23
120	Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2010 , 17, 714-9	3.4	23
119	Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2204-11	5.1	27
118	Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. <i>Clinical Infectious Diseases</i> , 2010 , 51, 1209-16	11.6	51

117	Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfecting with HIV and hepatitis C virus. <i>Clinical Infectious Diseases</i> , 2010 , 51, 788-95	11.6	128
116	Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfecting patients. <i>Aids</i> , 2010 , 24, 975-82	3.5	9
115	Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfecting patients using transient elastometry. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 801-7	2.2	23
114	Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. <i>Antiviral Therapy</i> , 2010 , 15, 753-63	1.6	39
113	HAART and the liver: friend or foe?. <i>European Journal of Medical Research</i> , 2010 , 15, 93-6	4.8	5
112	Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice. <i>HIV Medicine</i> , 2010 , 11, 439-47	2.7	14
111	Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 5185-96	5.9	10
110	Decrease in serial prevalence of coinfection with hepatitis C virus among HIV-infected patients in Spain, 1997-2006. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1467-70	11.6	39
109	Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfecting patients with advanced immunosuppression. <i>Clinical Infectious Diseases</i> , 2009 , 49, e84-91	11.6	12
108	Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. <i>Gut</i> , 2009 , 58, 1654-60	10.2	21
107	Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients. <i>HIV Clinical Trials</i> , 2009 , 10, 276-81		1
106	The changing face of HIV/AIDS in treated patients. <i>Current HIV Research</i> , 2009 , 7, 365-77	1.3	25
105	Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2009 , 49, 1274-82	11.6	62
104	Fast fibrosis progression between repeated liver biopsies in patients coinfecting with human immunodeficiency virus/hepatitis C virus. <i>Hepatology</i> , 2009 , 50, 1056-63	11.2	201
103	Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 249-58	3.4	23
102	Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2009 , 50, 684-92	13.4	17
101	The Spanish HIV BioBank: a model of cooperative HIV research. <i>Retrovirology</i> , 2009 , 6, 27	3.6	124
100	A review of current anti-HCV treatment regimens and possible future strategies. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 417-33	4	19

99	Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 445-9	3.1	39
98	Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 390-6	3.1	13
97	Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 178-83	5.1	13
96	High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. <i>Liver International</i> , 2008 , 28, 781-6	7.9	68
95	Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. <i>Journal of Hepatology</i> , 2008 , 49, 916-22	13.4	36
94	Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1365-73	5.1	48
93	Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 793-6	5.1	15
92	Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfecting patients. <i>Aids</i> , 2008 , 22, 923-30	3.5	15
91	Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 925-32	5.1	25
90	Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users. <i>Journal of Infectious Diseases</i> , 2008 , 197, 405-10	7	57
89	Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. <i>HIV Clinical Trials</i> , 2008 , 9, 309-13		7
88	Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir. <i>Antiviral Therapy</i> , 2008 , 13, 429-438	1.6	46
87	Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. <i>Hepatology</i> , 2007 , 46, 622-30	11.2	154
86	Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfecting patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 87-91	5.1	3
85	Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 342-6	5.1	117
84	Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfecting patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 1347-54	5.1	41
83	The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. <i>Clinical Infectious Diseases</i> , 2007 , 45, 969-74	11.6	155
82	Management of HCV-related end-stage liver disease in HIV-coinfecting patients. <i>AIDS Reviews</i> , 2007 , 9, 131-9	1.5	12

81	Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. <i>Antiviral Therapy</i> , 2007 , 12, 1225-35	1.6	13
80	Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. <i>Antiviral Therapy</i> , 2007 , 12, 523-529	1.6	15
79	Predictors of Severe Haematological Toxicity Secondary to Pegylated Interferon plus Ribavirin Treatment in HIV-HCV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 1225-1236	1.6	25
78	Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 140-6	5.1	22
77	Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfecting patients by simple non-invasive indexes. <i>Gut</i> , 2006 , 55, 409-14	19.2	97
76	Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 1016-7	5.1	17
75	Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfecting patients with decompensated cirrhosis. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 1236-41	1.6	17
74	Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 4455-8	9.7	29
73	Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. <i>Aids</i> , 2006 , 20, 49-57	3.5	121
72	Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2006 , 13, 449-56	3.4	17
71	Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 839-46	1.6	11
70	Incidence of and Risk Factors for Insulin Resistance in Treatment-Naive HIV-Infected Patients 48 Weeks after Starting Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 529-535	1.6	26
69	Antiretroviral Therapy Based on Protease Inhibitors as a Protective Factor against Liver Fibrosis Progression in Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006 , 11, 839-846	1.6	30
68	Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. <i>Journal of Infectious Diseases</i> , 2005 , 192, 1566-76	7	29
67	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005 , 41, 779-89	11.2	214
66	Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C. <i>Hepatology</i> , 2005 , 42, 498; author reply 498-9	11.2	
65	HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology</i> , 2005 , 42, 496-7; author reply 497	11.2	2
64	Reply:. <i>Hepatology</i> , 2005 , 42, 497-497	11.2	

63	Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. <i>Journal of Infection</i> , 2005 , 51, 195-200	18.9	42
62	Progression of liver fibrosis in patients coinfectd with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 55, 417-9	5.1	26
61	Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 915-21	1.6	31
60	Bilateral enophthalmos as a manifestation of HIV infection-related lipoatrophy. <i>HIV Medicine</i> , 2004 , 5, 448-9	2.7	8
59	Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus-co-infected patients: still a role for liver biopsy?. <i>Aids</i> , 2004 , 18, 1746-8	3.5	5
58	Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. <i>Aids</i> , 2004 , 18, 767-74	3.5	119
57	FREQUENCY OF VISCERAL LEISHMANIASIS RELAPSES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004 , 70, 298-301	3.2	24
56	DETECTION OF LEISHMANIA INFANTUM KINETOPLAST DNA IN PERIPHERAL BLOOD FROM ASYMPTOMATIC INDIVIDUALS AT RISK FOR PARENTERALLY TRANSMITTED INFECTIONS: RELATIONSHIP BETWEEN POLYMERASE CHAIN REACTION RESULTS AND OTHER LEISHMANIA INFECTION MARKERS. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004 , 70, 545-8	3.2	37
55	Detection of Leishmania infantum kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other Leishmania infection markers. <i>American Journal of Tropical Medicine and Hygiene</i> , 2004 , 70, 545-8	3.2	19
54	Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. <i>HIV Clinical Trials</i> , 2003 , 4, 337-46		66
53	Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 194-6	5.3	5
52	Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfectd with human immunodeficiency virus and hepatitis C virus. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 675-80	5.3	26
51	Bone involvement and abcess formation by neutrophil-rich CD30+ anaplastic large-cell lymphoma mimicking skeletal infection in an AIDS patient. <i>Journal of Infection</i> , 2003 , 47, 73-6	18.9	15
50	Necrotizing granulomatous vasculitis in advanced HIV infection. <i>Journal of Infection</i> , 2003 , 47, 333-5	18.9	13
49	Leishmania infantum (Protozoa, kinetoplastida): transmission from infected patients to experimental animal under conditions that simulate needle-sharing. <i>Experimental Parasitology</i> , 2002 , 100, 71-4	2.1	25
48	Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2002 , 21, 775-81	5.3	58
47	Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 762-7	9.7	42
46	The high sensitivity of a PCR-ELISA in the diagnosis of cutaneous and visceral leishmaniasis caused by Leishmania infantum. <i>Annals of Tropical Medicine and Parasitology</i> , 2002 , 96, 669-77		19

45	Leishmania spp infection in injecting drug users. <i>Lancet, The</i> , 2002 , 360, 950-1	4.0	11
44	Transient Rebounds of Low-Level Viraemia among HIV-Infected Patients under Haart are Not Associated with Virological or Immunological Failure. <i>Antiviral Therapy</i> , 2002 , 7, 251-256	1.6	42
43	Evidence of increased risk for leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 354-7	5.3	10
42	HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 46-8	5.3	12
41	Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4 + T-cell counts. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001 , 20, 253-9	5.3	7
40	False-positive results of leishmanin skin test due to phenol-containing diluent. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2001 , 95, 173-4	2	7
39	Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood. <i>Liver</i> , 2001 , 21, 410-4		7
38	Low levels of HIV-1 plasma viral load in patients infected with HIV-1 subtype b and advanced immunosuppression. <i>Journal of Infection</i> , 2001 , 42, 4-7	18.9	2
37	Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. <i>Clinical Infectious Diseases</i> , 2001 , 32, 633-5	11.6	31
36	HIV-1 progression in hepatitis-C-infected drug users. <i>Lancet, The</i> , 2001 , 357, 1362-3	4.0	2
35	Diagnosis of infections with Leishmania infantum using PCR-ELISA. <i>Parasitology</i> , 2001 , 122, 607-15	2.7	45
34	Structural normalization of the lymphoid tissue in asymptomatic HIV-infected patients after 48 weeks of potent antiretroviral therapy. <i>Aids</i> , 2001 , 15, 2371-8	3.5	5
33	CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients. <i>Clinical and Experimental Immunology</i> , 2000 , 119, 493-8	6.2	46
32	Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999 , 18, 733-6	5.3	13
31	Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. <i>Journal of Hepatology</i> , 1999 , 31, 777-8	13.4	18
30	High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. <i>American Journal of Tropical Medicine and Hygiene</i> , 1999 , 61, 766-9	3.2	55
29	Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1998 , 17, 167-70	5.3	35
28	Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. <i>Clinical Infectious Diseases</i> , 1998 , 26, 218-9	11.6	19

27	Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine. <i>Aids</i> , 1998 , 12, 395-8	3.5	8
26	Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 315-6	9.7	7
25	Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 2419-22	9.7	44
24	Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naïve and antiretroviral-experienced HIV-infected patients in Spain. <i>Aids</i> , 1998 , 12, 1015-20	3.5	13
23	Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naïve patients from 1989 to 1996. <i>Aids</i> , 1997 , 11, 1184-6	3.5	29
22	Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. <i>Journal of Hepatology</i> , 1997 , 27, 25-9	13.4	52
21	Frequency of subclinical visceral leishmaniasis in HIV-1-infected patients in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1996 , 15, 263-4	5.3	11
20	Specificity of a commercial indirect immunofluorescence technique in the diagnosis of visceral leishmaniasis in patients infected with HIV-1. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1996 , 90, 383	2	10
19	Association between hepatitis C virus seroreactivity and HIV infection in non-intravenous drug abusing prostitutes. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1995 , 14, 460-4	5.3	8
18	Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. <i>Journal of Infectious Diseases</i> , 1994 , 169, 267-73	7	18
17	Isolated renal mucormycosis in two AIDS patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1994 , 13, 430-2	5.3	28
16	High rate of nonspecific anti-hepatitis C reactivity amongst homosexual men in comparison with that found in other sexually active groups and blood donors. Viral Hepatitis and AIDS Study Group. <i>Journal of Internal Medicine</i> , 1994 , 236, 73-7	10.8	9
15	Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. <i>Journal of Hepatology</i> , 1993 , 17, 288-93	13.4	51
14	HIV-2 Infection in high-risk individuals in Spain. <i>Transfusion Science</i> , 1993 , 14, 167-172		1
13	Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993 , 12, 827-31	5.3	48
12	Failure to detect silent HIV infection by polymerase chain reaction in subjects at risk for heterosexually transmitted HIV type 1 infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993 , 12, 663-7	5.3	8
11	Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?. <i>Aids</i> , 1992 , 6, 1499-503	3.5	62
10	HIV-1 infection among non-intravenous drug user female prostitutes in Spain. No evidence of evolution to pattern II. <i>Aids</i> , 1992 , 6, 1365-9	3.5	14

9	Isolated anti-HBc and hepatitis B virus occult infection. <i>Vox Sanguinis</i> , 1991 , 61, 140	3.1	8
8	HIV-1-Ag as the one marker in the early stage of HIV-1 infection. <i>Vox Sanguinis</i> , 1991 , 60, 241	3.1	1
7	Absence of HTLV-I and HTLV-II infection in prostitutes in the area of Seville, Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1991 , 10, 773-5	5.3	6
6	Hepatitis C virus infection in sexually promiscuous groups. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1990 , 9, 610-2	5.3	25
5	Predictive value of the presence of P24 antigen in persons with antibodies to human immunodeficiency virus in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1989 , 8, 244-8	5.3	2
4	Can the determination of HIV-1 Ag in serum be useful in identifying hemophiliac patients who end up developing AIDS?. <i>Vox Sanguinis</i> , 1989 , 56, 134-5	3.1	
3	Recombinant EIA for anti-HIV testing is more specific than conventional EIA. <i>Vox Sanguinis</i> , 1988 , 54, 62-3	3.1	4
2	Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. <i>Lancet, The</i> , 1988 , 1, 1245-9	4.0	57
1	Rotative agitation RIA. A high sensitivity technique for hepatitis B surface antigen (HBsAg) determinations. <i>Journal of Hepatology</i> , 1986 , 3, 356-62	13.4	4